No / Purpose: Does a physiologically plausible model of the retinal ganglion cell (RGC) receptive field (RF) predict the spatial tuning properties of the Hermann Grid Illusion (HGI)? Methods: The spatial tuning of a single intersection HGI was measured psychophysically in normal observers using a nulling technique at different vertical grid line luminances. We used a model based upon a standard RGC RF, balanced to produce zero response under uniform illumination, to predict the response of the model cell to the equivalent range of stimulus conditions when placed in either the 'street' or the 'intersection' of a single element of a Hermann grid. We determined the equivalent of the nulling luminance required to balance these responses and minimise the HGI. Results: The model and the psychophysical data demonstrated broad spatial tuning with similarly shaped tuning profiles and similar strengths of illusion. The line width at the peak of the model tuning function was around twice the model RGC RF centre size. Modelling the psychophysical functions gave RF centre sizes smaller than expected from human anatomical evidence but similar to that suggested by primate physiological evidence. In the model and psychophysically the strength of the illusion varied with the luminance of the vertical grid line when HGI strength was expressed as a Michelson nulling contrast, but this effect was smaller when HGI strength was expressed as a nulling luminance. Conclusions: The shape, width, height and position of the spatial tuning function of the HGI can be well modelled by a RGC RF based model. The broad tuning of these functions does not appear to require a broad range of different cell sizes either in the retina or later in the visual pathway.

No / Purpose: To develop a perimetric test strategy, Structure Estimation of Minimum Uncertainty (SEMU), that uses structural information to drive stimulus choices. Methods: Structure Estimation of Minimum Uncertainty uses retinal nerve fiber layer (RNFL) thickness data as measured by optical coherence tomography to predict perimetric sensitivity. This prediction is used to set suprathreshold levels that then alter a prior probability distribution of the final test output. Using computer simulation, we studied SEMU’s performance under three different patient error response conditions: No Error, Typical False Positive errors, and Extremely Unreliable patients. In experiment 1, SEMU was compared with an existing suprathreshold cum thresholding combination test procedure, Estimation of Minimum Uncertainty (EMU), on single visual field locations. We used these results to finalize SEMU parameters. In experiment 2, SEMU was compared with full threshold (FT) on 163 glaucomatous visual fields. Results: On individual locations, SEMU has similar accuracy to EMU, but is, on average, one presentation faster than EMU. For the typical false-positive error condition, SEMU has significantly lower error compared with FT (SEMU average 0.33 dB lower; p < 0.001) and the 90% measured sensitivity range for SEMU is also smaller than that for FT. For unreliable patients, however, FT has lower mean and SD of error. Structure Estimation of Minimum Uncertainty makes significantly fewer presentations than FT (1.08 presentation on average fewer in a typical false-positive condition; p < 0.001). Assuming that a location in the field is marked abnormal if it falls below the 5th percentile of normal, SEMU has a false-positive rate of less than 10% for all error conditions compared with FT’s rate of 20% or more. Conclusions: On average, simulations show that using RNFL information to guide stimulus placement in a perimetric test procedure maintains accuracy, improves precision, and decreases test duration for patients with less than 15% false-positive rates.

Yes / Purpose.: To establish whether a clinically exploitable relationship exists between surrogate measures of retinal ganglion cell number and functional sampling density and visual contrast sensitivity in healthy young eyes. Methods.: Psychometric functions for contrast detection were measured at 9° eccentricity in superior and inferior visual field from 20 healthy adults (age 23–43, median 26 years). Functions were compared with corresponding localized regions of retinal nerve fiber layer (RNFL) thickness measured by optical coherence tomography, a surrogate of retinal ganglion cell number, and to grating resolution acuity, a psychophysical surrogate of retinal ganglion cell sampling density. Correlations between psychometric function parameters and retinal ganglion cell surrogates were measured by Spearman's rank correlation. Results.: All measures exhibited a 2- to 4-fold variation in our sample. Despite this, correlations between measures were weak. Correlations between psychometric function parameters (threshold, spread) and RNFL thickness ranged in magnitude from 0.05 to 0.19 (P = 0.43–0.85). Grating resolution was sampling limited for 16 of 20 participants in superior visual field, and for 12 of 20 participants in inferior visual field. Correlations between psychometric function parameters and grating resolution acuities ranged in magnitude from 0.05 to 0.36 (P = 0.12–0.85) when all data were considered, and from 0.06 to 0.36 (P = 0.26–0.87) when only sampling-limited data were considered. Conclusions.: Despite considerable variation in both psychometric functions for contrast detection and surrogate measures of retinal ganglion cell number and sampling density among healthy eyes, relationships between these measures are weak. These relationships are unlikely to be exploitable for improving clinical tests in healthy populations.

Purpose: To review the roles of the different vascular beds nourishing the inner retina [retinal ganglion cells (RGCs)] during normal development of the human eye, using our own tissue specimens to support our conclusions. Methods: An extensive search of the appropriate literature included PubMed, Google scholar, and numerous available textbooks. In addition, choroidal and retinal NADPH-diaphorase stained whole mount preparations were investigated. Results: The first critical interaction between vascular bed and RGC formation occurs in the sixth to eighth month of gestation leading to a massive reduction of RGCs mainly in the peripheral retina. The first 3 years of age are characterized by an intense growth of the eyeball to near adult size. In the adult eye, the influence of the choroid on inner retinal nutrition was determined by examining the peripheral retinal watershed zones in more detail. Conclusion: This delicately balanced situation of RGC nutrition is described in the different regions of the eye, and a new graphic presentation is introduced to combine morphological measurements and clinical visual field data.

Les Rétinal déshydrogénases (RALDHs) catalysent irréversiblement la déshydrogénation du Rétinal en Acide Rétinoïque (AR) qui est impliqué dans l’embryogenèse et la différenciation tissulaire. Pour comprendre le rôle dans la biosynthèse de l’AR des RALDHs type 3 et 4 de souris, nous avons déterminé leurs propriétés cinétiques ainsi que leur comportement en présence de différents inhibiteurs. Les tests enzymatiques sont effectués avec une préparation d’enzyme recombinante, tagguée avec 6 histidines, purifiée sur colonne Ni-NTA (Qiagen). L’activité enzymatique est évaluée en quantifiant la production d’AR par chromatographie liquide à haute performance (HPLC) en phase inversée. Les constantes cinétiques ont été déterminées pour les isomères du rétinal tout-trans, 9-cis et 13-cis. La RALDH4 catalyse les isomères 9-cis et 13-cis de rétinal, elle présente un faible KM (3μM) pour les deux isomères et a une efficacité catalytique élevée pour le 9-cis rétinal 3.4 fois supérieure au 13-cis rétinal. La RALDH3 est spécifique au tout-trans rétinal avec un KM de 4 μM et une efficacité élevée. β-Ionone, inhibiteur possible pour la RALDH4, inhibe l’activité avec le rétinal 9-cis et 13-cis, mais n’influence pas l’activité de la RALDH3. Le para-hydroxymercuribenzoïque (p-HMB) inhibe l’activité de deux isoenzymes. Le cation MgCl2 augmente par 3 fois l’oxydation du rétinal 13-cis par la RALDH4, diminue l’oxydation du 9-cis rétinal et influence faiblement la RALDH3. Ces données enrichissent les connaissances sur les caractéristiques cinétiques des RALDHs recombinantes de souris de types 3 et 4 et fournissent des éclaircissements sur la biogenèse de l’acide rétinoïque in vivo. / SUMMARY Retinal dehydrogenases (RALDHs) catalyze the dehydrogenation of retinal into retinoic acids (RA) that are required for embryogenesis and tissue differentiation. This study sought to determine the detailed kinetic properties of 2 mouse RALDHs, namely RALDH3 and 4, for retinal isomer substrates, to better define their specificities in RA isomer synthesis. RALDH3 and 4 were expressed as His-tagged proteins and affinity-purified. RALDH3 oxidized all-trans retinal with high catalytic efficiency but did not show activity for either 9-cis or 13-cis retinal substrates. RALDH4 was inactive for all-trans retinal substrate, exhibited high activity for 9-cis retinal oxidation, and oxidized 13-cis retinal with lower catalytic efficiency. β-ionone, a potent inhibitor of RALDH4 activity, suppressed 9-cis and 13-cis retinal oxidation competitively, but had no effect on RALDH3 activity. The p-HMB inhibited the activity for both RALDH3 and RALDH4. The divalent cation MgCl2 activated 13-cis retinal oxidation by RALDH4 by 3-fold, slightly decreased 9-cis retinal oxidation, and did not significantly influence RALDH3 activity. These data extend the kinetic characterization of RALDH3 and 4, providing their specificities for retinal isomer substrates, which should help in determining their functions in the synthesis of RAs in specific tissues.

Thesis (M.S.)--Uniformed Services University of the Health Sciences, 2005. / Running title: Seasonal affective disorder and melanopsin. Typescript (photocopy).

Les dystrophies rétiniennes héréditaires (DRH) sont un groupe de maladies génétiquement et cliniquement hétérogènes, lesquelles se caractérisent par une perte progressive de la vision. La choroïdérémie (CHM) est une choriorétinopathie qui représente environ 3% des DRH. Elle se caractérise par une cécité nocturne durant l’enfance suivie par une perte du champ visuel périphérique lente et progressive. Cela aboutit à une cécité vers l’âge de 40 à 50 ans. Généralement, la vision centrale demeure préservée plus longtemps. Génétiquement, la maladie est causée par des mutations dans le gène CHM localisé dans le chromosome X qui code pour la Rab Escort Protein 1 (REP1).Cette protéine est impliquée dans la prénylation des Rab GTPasas qui régulent le trafic vésiculaire au sein de la cellule. La plupart des mutations responsables de la maladie sont des mutations pertes de fonction. La conséquence de ces mutations est l’absence de REP1 entrainant un défaut de prénylation des Rabs. Ce qui cause la dégénérescence des photorécepteurs, de l’épithélium pigmentaire rétinien (EPR) et de la choroïde. À ce jour, il n’existe pas de thérapie pour la CHM. Cependant, le diagnostic précoce de la maladie et son évolution lente donnent une fenêtre thérapeutique large et en font un candidat idéal pour la réussite d’un traitement.En raison de l’absence d’un modèle animal pertinent pour tester de nouvelles thérapies pour cette maladie, nous avons développé un modèle cellulaire humain d’EPR in vitro dérivé des cellules pluripotentes induites propres au patient. Ce tissu est morphologiquement et fonctionnellement représentatif de l’EPR in vivo et reproduit les défauts biochimiques de prénylation présents dans la CHM. De ce fait, il s’agit d’un modèle puissant pour évaluer l’efficacité de différentes approches thérapeutiques. Dans cette perspective, nous avons étudié une approche de thérapie génique par AAV2/5 afin de fournir le gène CHM dans le cas particulier de mutation faux sens et l’utilisation d’une translational read-through inducing drug (TRID) PTC124 pour le traitement des mutations non-sens.J’ai démontré pour la première fois la faisabilité de la thérapie génique pour la CHM dans le cas d’une expression résiduelle de REP1 muté, permettant de considérer les patients porteurs de mutations faux sens comme éligible à des essais cliniques de thérapie génique. De plus, j’ai démontré que l’efficacité de PTC124 peut être dépendante du type cellulaire. Dans l’ensemble, mes résultats suggèrent que l’efficacité de la molécule semblerait dépendre de la conservation de l’acide aminé muté et de sa localisation dans le domaine fonctionnel de REP1. Nous avons ainsi mis en valeur que le contexte génétique devrait être pris en compte dans la perspective d’une thérapie avec TRID pour cette maladie ainsi que d’autres pathologies.Pour conclure, j’ai souligné le potentiel prédictif du modèle d’EPR dérivé d’iPSc propre au patient pour évaluer de nouvelles approches thérapeutiques en l’absence d’un modèle animal approprié avant les essais cliniques. / Inherited retinal dystrophies (IRDs) are a class of genetically and clinically heterogeneous diseases, which are characterized by a progressive loss of vision. Choroideremia (CHM) is a chorioretinopathy, which accounts for ~3% of all IRDs. It is characterized by night blindness in childhood, followed by slow and progressive loss of the peripheral visual field. This results in legal blindness by the fourth to fifth decade of life. Generally, central vision is preserved till late in life. Genetically, the disease is caused by mutations in the CHM gene located on the X chromosome and encoding the Rab Escort Protein 1 (REP1). This protein is involved in the prenylation of Rab GTPasas, which regulate vesicular cell trafficking. Most of the disease-causing mutations are loss-of-function and the absence of REP1 leads to a Rab prenylation defect and subsequent degeneration of photoreceptors, retinal pigment epithelium (RPE) and underlying choroid. To date, an established therapy is not available for CHM, but the early diagnosis and its slow evolution provide a large therapeutic window, that renders this disease a good candidate for successful treatment.In order to palliate the lack of a pertinent animal model for testing novel disease therapies, we developed a human cellular model using patient-specific induced pluripotent stem cells (iPSc)-derived RPE. This tissue is morphologically and functionally representative of the RPE in vivo, and reproduces the biochemical prenylation defect present in CHM. Therefore, it is a powerful model to evaluate the efficacy of different therapeutic approaches. Along this line, we investigated a gene augmentation approach, via AAV2/5 delivery of the CHM gene in the particular case of a CHM missense mutation, and the use of the translational read-through inducing drug (TRID) PTC124 for treating CHM nonsense mutations.I demonstrated for the first time the feasibility of gene augmentation therapy for CHM in the case of residual mutated REP1 expression, suggesting that missense-carrying patients can be considered for inclusion in clinical gene therapy trials. Moreover, I showed that the efficiency of PTC124 may be dependent on the cell type. In addition, my results suggest that drug efficiency likely depends on the conservation of the mutated amino acid residue and its localization with regards to REP1 functional domains. We thus highlight that genetic considerations should be taken into account when considering TRID therapy for this and other disorders.Taken together, I highlighted the predictive potential of the patient-specific iPSc-derived RPE model for screening of novel and varied therapeutic approaches in the absence of a suitable animal model prior to clinical translation.

In Canada alone, there were an estimated 800,000 visually impaired people in 2007, costing the federal government an annual amount of $15.8 billion in services, treatments and lost revenue. These costs are estimated to double by the year 2032, as the population ages. The leading causes of visual impairment and blindness is retinal degeneration, characterized by the progressive death of retinal cells. The research presented in this PhD thesis aimed to prevent retinal degeneration by over-expressing the X-linked Inhibitor of Apoptosis (XIAP) in retinal cells using plasmid and adeno-associated viral vectors. The work is divided into four sequential chapters targeted at developing an anti-apoptotic gene therapy strategy to prevent retinal cell death. The first chapter examines XIAP gene therapy in the treatment of Leber’s Hereditary Optic Neuropathy (LHON). In vitro studies using the 661W cone-photoreceptor cell line showed that XIAP over-expression significantly lowers cell death when 661W cells are exposed to a number of apoptotic stimuli. In a mouse model of Leber’s Hereditary Optic Neuropathy (LHON), XIAP expression in retinal ganglion cells (RGCs) protected the ultrastructure of the RGC axons within the optic nerve, in addition to providing evidence of functional protection. The second and third chapters further examine the potential for XIAP gene therapy in the treatment of retinal disease by developing an in vivo model of retinal detachment in cats, followed by evaluating the efficacy of XIAP gene therapy intervention. When XIAP was over-expressed in the photoreceptor cells, there was significant structural protection and trends in preservation of function in this model of degeneration. Finally, the fourth chapter explores an alternate method to viral gene therapy by evaluating the efficacy and toxicity of chitosan microparticles as a protein delivery system to the retina. Results show that chitosan microparticles are mucosal-adhesive and are non-toxic at low concentrations in vitro in 661W cells and in vivo in rats. This thesis work provides strong evidence that XIAP gene therapy is an effective method for preventing retinal degeneration, and works as a broad spectrum gene therapy strategy that can be applied to different forms of retinal degeneration.

L’objectif de cette thèse est la validation fonctionnelle d’implants rétiniens pour la restauration fonctionnelle de la vision chez des patients non voyants suite à la perte de leurs photorécepteurs. Ce travail a été réalisé sur modèle animal et a évalué expérimentalement de nouveaux protocoles de stimulation. Tout d’abord nous avons utilisé la technique de spectroscopie d’impédance pour simuler mathématiquement l’interface tissu-implantafin de caractériser la présence d’un espace entre le tissu et l’implant. La seconde partie compare par imagerie optique (IO) les caractéristiques de la réponse corticale évoquée par stimulation visuelle ou électrique de la rétine par prothèse sous rétinienne. Nous avons retrouvé que la taille de l’activation par l’implant rétinien est beaucoup plus grande que son correspondant visuel. Dans une troisième partie, est réalisée une évaluation in vitro de la performance des stimulations sur rétine isolée pour définir comment les cellules ganglionnaires réagissent à différents modes de stimulations. Ce travail a permis d’établir la courbe des réponses en fonction de l’intensité des stimulations électriques. Enfin, la thèse décrit un modèle animal de dégénérescence rétinienne qui présente des désorganisations de la rétine externe. Une analyse en IO a été réalisée sur ce modèle afin d’évaluer la réponse corticale aux stimuli visuels et électriques. Ce travail de thèse, par des approches physiques et physiologiques complémentaires, apporte un certain nombre de réponses qui devraient permettre d’améliorer l’utilisation de futures prothèses rétiniennes par une adaptation physique des matrices d’électrodes ou des patrons de stimulations utilisées / The aim of this thesis is the functional validation of retinal implants used for vision restoration in blind patients due to the loss of photoreceptors. This work was designed to develop an animal model to experimentally validate prototypes of new implants and new stimulation protocols pattern. Firstly we used the technique of impedance spectroscopy to simulate mathematically the tissue/implant interface. These data confirm the importance of reducing the space between the stimulating electrodes and retinal tissue, as well as the importance of physical characteristics of the electrical stimulus used. In a second approach, we have compared responses of visual cortical neuronal population using optical imaging (OI), evoked either by visual or electric retinal stimulation through subretinal prosthesis. This approach has demonstrated that the stimulation of an electrode induces cortical activation that the size of the cortical response to the retinal implant stimulation is much larger than its corresponding visual stimulus. In the third part, I performed in vitro experiment to measure the performance of stimulation at the level of ganglion cells of isolated retina. We have quantified the response curve as a function of the intensity of the electrical stimulation. Finally, the thesis describes a new animal model of outter retinal degeneration. OI was also performed on this model to assess the response to the visual and retinal prosthesis stimulations. This thesis, through complementary physical and physiological approaches, provides a number of responses that can potentially improve the use of retinal prostheses through specification of their design or patterns of stimulation.

Les Rétinal déshydrogénases (RALDHs) catalysent irréversiblement la déshydrogénation du Rétinal en Acide Rétinoïque (AR) qui est impliqué dans l’embryogenèse et la différenciation tissulaire. Pour comprendre le rôle dans la biosynthèse de l’AR des RALDHs type 3 et 4 de souris, nous avons déterminé leurs propriétés cinétiques ainsi que leur comportement en présence de différents inhibiteurs. Les tests enzymatiques sont effectués avec une préparation d’enzyme recombinante, tagguée avec 6 histidines, purifiée sur colonne Ni-NTA (Qiagen). L’activité enzymatique est évaluée en quantifiant la production d’AR par chromatographie liquide à haute performance (HPLC) en phase inversée. Les constantes cinétiques ont été déterminées pour les isomères du rétinal tout-trans, 9-cis et 13-cis. La RALDH4 catalyse les isomères 9-cis et 13-cis de rétinal, elle présente un faible KM (3μM) pour les deux isomères et a une efficacité catalytique élevée pour le 9-cis rétinal 3.4 fois supérieure au 13-cis rétinal. La RALDH3 est spécifique au tout-trans rétinal avec un KM de 4 μM et une efficacité élevée. β-Ionone, inhibiteur possible pour la RALDH4, inhibe l’activité avec le rétinal 9-cis et 13-cis, mais n’influence pas l’activité de la RALDH3. Le para-hydroxymercuribenzoïque (p-HMB) inhibe l’activité de deux isoenzymes. Le cation MgCl2 augmente par 3 fois l’oxydation du rétinal 13-cis par la RALDH4, diminue l’oxydation du 9-cis rétinal et influence faiblement la RALDH3. Ces données enrichissent les connaissances sur les caractéristiques cinétiques des RALDHs recombinantes de souris de types 3 et 4 et fournissent des éclaircissements sur la biogenèse de l’acide rétinoïque in vivo. / SUMMARY Retinal dehydrogenases (RALDHs) catalyze the dehydrogenation of retinal into retinoic acids (RA) that are required for embryogenesis and tissue differentiation. This study sought to determine the detailed kinetic properties of 2 mouse RALDHs, namely RALDH3 and 4, for retinal isomer substrates, to better define their specificities in RA isomer synthesis. RALDH3 and 4 were expressed as His-tagged proteins and affinity-purified. RALDH3 oxidized all-trans retinal with high catalytic efficiency but did not show activity for either 9-cis or 13-cis retinal substrates. RALDH4 was inactive for all-trans retinal substrate, exhibited high activity for 9-cis retinal oxidation, and oxidized 13-cis retinal with lower catalytic efficiency. β-ionone, a potent inhibitor of RALDH4 activity, suppressed 9-cis and 13-cis retinal oxidation competitively, but had no effect on RALDH3 activity. The p-HMB inhibited the activity for both RALDH3 and RALDH4. The divalent cation MgCl2 activated 13-cis retinal oxidation by RALDH4 by 3-fold, slightly decreased 9-cis retinal oxidation, and did not significantly influence RALDH3 activity. These data extend the kinetic characterization of RALDH3 and 4, providing their specificities for retinal isomer substrates, which should help in determining their functions in the synthesis of RAs in specific tissues.